Alchemist Overseas

A description of a 20mg tirzepatide injection indicates that it is a compounded, unapproved product and not an FDA-approved medication. The maximum approved dosage for tirzepatide, sold under brand names like Mounjaro and Zepbound, is 15 mg per week. Compounded versions are not evaluated for safety, quality, or effectiveness. FDA-approved tirzepatide formulations

• Mounjaro: Prescribed for type 2 diabetes.
• Zepbound: Prescribed for chronic weight management and obstructive sleep apnea in adults with obesity. 

Both Mounjaro and Zepbound are administered as a once-weekly subcutaneous injection. FDA-approved dosage for tirzepatideThe typical dosing for both Mounjaro and Zepbound involves a gradual increase to minimize side effects. 

• Starting dose: 2.5 mg once weekly for the first 4 weeks.
• Dose escalation: The dosage may be increased by 2.5 mg increments every 4 weeks.
• Maximum approved dose: 15 mg once weekly. 

Mazdutide 10 mg is a high-dose, once-weekly injectable medication being studied for weight management and type 2 diabetes. As a dual agonist, it activates both glucagon-like peptide-1 (GLP-1) and glucagon receptors to reduce appetite and increase energy expenditure. The 10 mg dose was evaluated in a phase 1b trial and showed significant weight loss compared to a placebo over a 16-week period. 


Mazdutide is a synthetic peptide analogue that acts as a dual agonist for two different receptors: 

• GLP-1 receptor activation: Similar to other GLP-1 agonists, this action helps to promote insulin secretion, suppress appetite, and slow gastric emptying, which leads to lower blood glucose and reduced food intake.
• Glucagon receptor activation: Unlike GLP-1 agonists, mazdutide also activates the glucagon receptor. This increases the body's energy expenditure and improves how the liver processes fat, leading to enhanced weight loss. 

IGF-1 DES is a synthetic, truncated version of the naturally occurring peptide hormone Insulin-like Growth Factor-1 (IGF-1). It is primarily used as an injectable research chemical for its potent, targeted effects on muscle growth and tissue repair, particularly in the bodybuilding community. Key characteristics and mechanism

• Truncated structure: IGF-1 DES is a shortened analog of IGF-1, lacking the first three amino acids at its N-terminus. This structural change significantly alters its function.
• Enhanced potency: Due to its altered structure, IGF-1 DES does not bind effectively to insulin-like growth factor-binding proteins (IGFBPs), which normally inhibit IGF-1's activity. This allows more of the peptide to be "free" and active, making it up to 10 times more potent for local anabolic effects compared to standard IGF-1.
• Short half-life: Unlike other IGF-1 variants, IGF-1 DES has a very short half-life of only 20–30 minutes. This makes it ideal for targeted, site-specific injections, as its effects are localized to the area of administration rather than system-wide.
• Mechanism of action: It exerts its effects by binding to IGF-1 receptors on muscle tissue, tendons, and ligaments. This triggers a cascade of anabolic and regenerative signals that promote muscle protein synthesis and activate satellite cells, which are responsible for muscle repair and the potential creation of new muscle fibers (hyperplasia). 

Common applications (primarily off-label)

• Targeted muscle growth: Bodybuilders inject IGF-1 DES directly into specific "lagging" muscle groups to stimulate localized hypertrophy (muscle cell growth) and hyperplasia (increase in muscle cell number).
• Accelerated injury repair: It is used to aid in the recovery of muscle, tendon, and ligament injuries by promoting collagen synthesis and tissue regeneration.
• Performance enhancement: Athletes may use it to enhance nutrient uptake in targeted muscles, leading to a greater "pump" and supporting muscle repair after intense training. 

The description of IGF-1 LR3 injection is that it is a synthetic, long-acting analog of the naturally occurring hormone Insulin-like Growth Factor-1 (IGF-1). Due to its chemical modifications, it is significantly more potent and has a much longer half-life than natural IGF-1, making it a popular subject in research and in the bodybuilding community for its potent anabolic effects. What is IGF-1 LR3?

• A modified peptide: Its full name is Insulin-Like Growth Factor-1 Long Arginine 3. It is engineered with two changes: a substitution of arginine for glutamic acid at the third amino acid position and an additional 13 amino acids at its N-terminus.
• Resists binding proteins: These modifications cause IGF-1 LR3 to have very low affinity for insulin-like growth factor-binding proteins (IGFBPs). Since IGFBPs normally inhibit the action of IGF-1, this allows LR3 to remain active in the body for up to 120 times longer than standard IGF-1.
• Longer half-life: This prolonged activity gives IGF-1 LR3 an extended half-life of 20–30 hours, compared to the much shorter half-life of native IGF-1. 

Proposed effects and applications

• Muscle growth (hyperplasia): Unlike steroids that increase the size of existing muscle cells (hypertrophy), IGF-1 LR3 is thought to promote the growth of new muscle cells (hyperplasia).
• Body recomposition: It is believed to improve fat metabolism by encouraging fat burning for energy and improving the body's use of glucose. This can help reduce body fat while increasing lean muscle mass.

Based on clinical trial data, the 10 mg retatrutide injection is a novel, investigational triple-hormone agonist administered once weekly for the potential treatment of obesity, type 2 diabetes, and related metabolic conditions. The developer is the American pharmaceutical company Eli Lilly and Company. Key features

• Mechanism of action: Retatrutide is a "triple-G" agonist that mimics three gut hormones to regulate metabolism and appetite: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG). This triple-action approach is intended to provide more potent and comprehensive effects than single or dual-agonist therapies.
• Administration: The drug has a half-life of approximately six days, making it suitable for once-weekly subcutaneous (under the skin) injection.
• Clinical trials: As of October 2025, retatrutide is in Phase 3 clinical trials, with commercial availability expected in 2026 or later, assuming successful results and regulatory approval. The 10 mg dose was used in Phase 2 trials, along with other dose escalations. 

Potential uses and efficacy

• Obesity: Phase 2 trial results showed that participants who received a 12 mg dose of retatrutide experienced an average body weight reduction of 24.2% over 48 weeks. This level of weight loss rivals outcomes typically seen with bariatric surgery.
• Type 2 Diabetes: Studies have demonstrated that retatrutide can significantly improve glycemic control (measured by HbA1c levels) in people with type 2 diabetes while also reducing body weight.

Survodutide injection is an investigational drug being developed as a weekly subcutaneous injection for treating obesity and metabolic dysfunction-associated steatohepatitis (MASH). It is a dual agonist that activates both the glucagon and GLP-1 receptors, which are critical for metabolic control. Clinical trials have shown promising results, including significant weight loss in patients with obesity and a reduction in liver fat and fibrosis in patients with MASH. How it works

• Dual-agonist mechanism: Survodutide acts on both the glucagon receptor and the GLP-1 receptor.
• Benefits of dual-action: This dual action is thought to provide additional benefits beyond just weight reduction, such as increased energy expenditure and a direct reduction of fat in the liver. 

Uses and indications

• Obesity: Survodutide is being evaluated in Phase 3 clinical trials for the treatment of obesity and overweight.
• MASH: It is also being studied for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), including MASH-related liver fibrosis. 

HGH 191aa is a synthetic, recombinant human growth hormone (HGH) that is biologically identical to the natural growth hormone produced by the pituitary gland. The "191aa" signifies that it is a polypeptide chain composed of 191 amino acids, which is the precise structure of naturally occurring HGH. Composition and structure

• Amino acid sequence: The sequence of 191 amino acids is identical to that of human growth hormone derived from the pituitary gland.
• Recombinant technology: HGH 191aa is produced using advanced recombinant DNA technology. This process allows for the creation of a bio-identical version of the natural hormone.
• Formulation: It is typically supplied as a lyophilized (freeze-dried) powder in a vial, which is then reconstituted with sterile water for injection. 

Therapeutic usesHGH 191aa is medically prescribed to treat specific conditions related to growth hormone deficiency.